TScan's Losses Widen Amid Increased R&D Spend, Cash Reserves Dwindle

TL;DR

TCRX is burning cash fast on R&D, and while revenue is up, the widening losses mean they'll need more capital soon or risk stalling their promising pipeline.

AI Summary

TScan Therapeutics, Inc. (TCRX) reported a net loss of $35.71 million for the three months ended September 30, 2025, an increase from a net loss of $29.89 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $106.79 million, compared to $91.69 million in the prior year. Collaboration and license revenue significantly increased to $2.51 million for the three months ended September 30, 2025, up from $1.05 million in 2024, and to $7.76 million for the nine months, up from $2.15 million. Research and development expenses rose to $31.69 million for the quarter and $94.11 million for the nine months, reflecting increased investment in their novel T cell receptor (TCR)-engineered T cell (TCR-T) therapy product candidates. The company's cash and cash equivalents decreased from $178.69 million at December 31, 2024, to $169.51 million at September 30, 2025, while marketable securities saw a substantial drop from $111.42 million to $14.95 million over the same period. Total assets declined from $371.12 million to $262.23 million, and total stockholders' equity decreased from $240.97 million to $144.02 million, indicating significant capital consumption. The accumulated deficit grew to $481.89 million by September 30, 2025, from $375.10 million at December 31, 2024, underscoring the company's pre-revenue stage and high burn rate.

Why It Matters

TScan Therapeutics' widening net losses and declining cash reserves are critical for investors, signaling continued high burn rates typical of early-stage biotech. The substantial increase in R&D expenses to $94.11 million for the nine months ended September 30, 2025, indicates aggressive investment in their TCR-T therapy pipeline, which is crucial for future value creation but also a significant capital drain. For employees, sustained losses could raise concerns about long-term stability, while customers (future patients) depend on the successful, albeit costly, development of these novel cancer treatments. In the competitive oncology market, TScan's ability to secure additional funding and advance its unique platform against established players will dictate its viability and market position.

Risk Assessment

Risk Level: high — TScan Therapeutics exhibits a high-risk profile due to significant and increasing net losses, with an accumulated deficit of $481.89 million as of September 30, 2025. The company's cash and cash equivalents, combined with marketable securities, decreased from $290.11 million at December 31, 2024, to $184.45 million at September 30, 2025, indicating a rapid cash burn. Furthermore, the filing explicitly states, "We have incurred significant losses since inception, and we expect to incur losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future," and "We will need to obtain substantial additional funding to complete the development and any commercialization of our product candidates, if approved."

Analyst Insight

Investors should monitor TScan Therapeutics' upcoming financing activities closely, as the company's current cash position and burn rate suggest a need for substantial additional funding. Consider the potential for dilution from future equity raises and the impact on existing shareholder value. Evaluate the progress of their TCR-T therapy product candidates in clinical trials, as successful advancement could be a catalyst for future capital raises and long-term value.

Financial Highlights

debt To Equity

N/A

revenue

$7.76M

operating Margin

N/A

total Assets

$262.23M

total Debt

N/A

net Income

-$106.79M

eps

N/A

gross Margin

N/A

cash Position

$169.51M

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $106.79M — Net Loss (for the nine months ended September 30, 2025, increased from $91.69M in 2024)
• $7.76M — Collaboration and License Revenue (for the nine months ended September 30, 2025, up from $2.15M in 2024)
• $94.11M — Research and Development Expenses (for the nine months ended September 30, 2025, up from $77.99M in 2024)
• $169.51M — Cash and Cash Equivalents (as of September 30, 2025, down from $178.69M at December 31, 2024)
• $14.95M — Marketable Securities (as of September 30, 2025, down from $111.42M at December 31, 2024)
• $481.89M — Accumulated Deficit (as of September 30, 2025, up from $375.10M at December 31, 2024)
• 52,471,405 — Voting Common Stock Shares Outstanding (as of November 7, 2025)
• 4,276,588 — Non-Voting Common Stock Shares Outstanding (as of November 7, 2025)

Key Players & Entities

• TScan Therapeutics, Inc. (company) — registrant
• Nasdaq Global Market, LLC (company) — exchange where TCRX is registered
• SEC (regulator) — filing oversight
• Trump administration (person) — potential impact on fiscal, tax, and federal policies
• Russia (country) — involved in ongoing conflict impacting global economic uncertainty
• Ukraine (country) — involved in ongoing conflict impacting global economic uncertainty

FAQ

Risk Factors

• Substantial Capital Requirements and Burn Rate [high — financial]: The company has a history of net losses and an accumulated deficit of $481.89 million as of September 30, 2025. Continued significant investment in R&D, with expenses at $94.11 million for the nine months ended September 30, 2025, necessitates substantial capital, leading to a high burn rate and potential future financing needs.
• Dependence on Product Candidate Development [high — operational]: TScan's success hinges on the successful development and commercialization of its novel TCR-engineered T cell (TCR-T) therapy product candidates. Delays or failures in clinical trials or regulatory approvals could materially impact the company's future.
• Decreasing Cash and Marketable Securities [medium — financial]: Cash and cash equivalents decreased to $169.51 million as of September 30, 2025, from $178.69 million at December 31, 2024. Marketable securities saw a drastic reduction from $111.42 million to $14.95 million, indicating significant deployment of capital.
• Evolving Regulatory Landscape for Cell Therapies [medium — regulatory]: The development and approval of novel cell therapies like TCR-T face a complex and evolving regulatory environment. Changes in FDA guidelines or requirements could impact development timelines and costs.
• Competitive Landscape in Oncology [medium — market]: The oncology therapeutic area is highly competitive, with numerous established and emerging biotechnology companies developing innovative treatments. TScan faces competition from other cell therapy platforms and traditional oncology drugs.

Industry Context

The biotechnology sector, particularly in oncology, is characterized by intense innovation and high R&D investment. Companies like TScan are focused on developing novel cell therapies, such as TCR-T, to address unmet medical needs. The competitive landscape includes both large pharmaceutical companies and numerous smaller biotech firms, all vying for market share and regulatory approval.

Regulatory Implications

The development of advanced therapies like TCR-T is subject to stringent regulatory oversight from bodies such as the FDA. Navigating these regulations, including clinical trial requirements and manufacturing standards, presents significant hurdles and potential delays that can impact a company's timeline and financial resources.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Glossary

TCR-engineered T cell (TCR-T) therapy

A type of immunotherapy where a patient's T cells are genetically modified to express T cell receptors (TCRs) that can recognize and attack cancer cells. (This is the core technology platform for TScan Therapeutics, and its development is central to the company's strategy and financial performance.)

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total losses that have not been offset by profits. (TScan's substantial and growing accumulated deficit of $481.89 million highlights its pre-revenue status and significant historical investment without corresponding revenue generation.)

Burn Rate

The rate at which a company, typically a startup or one in a growth phase, spends its available capital to finance overhead before generating positive cash flow. (The company's increasing net loss and decreasing cash reserves indicate a high burn rate, which is a critical factor for investors to monitor regarding future funding needs.)

Year-Over-Year Comparison

TScan Therapeutics reported a widening net loss for the nine months ended September 30, 2025, to $106.79 million from $91.69 million in the prior year, reflecting increased R&D expenses. While collaboration and license revenue saw a significant surge to $7.76 million from $2.15 million, the company's cash position declined, and marketable securities were substantially reduced, indicating a higher capital consumption rate. The accumulated deficit also grew, underscoring the ongoing investment phase.

Key Financial Figures

• $0.0001 — which registered Voting Common Stock, $0.0001 par value per share TCRX The Nasdaq

Filing Documents

• tcrx-20250930.htm (10-Q) — 2586KB
• tcrx-ex31_1.htm (EX-31.1) — 23KB
• tcrx-ex31_2.htm (EX-31.2) — 23KB
• tcrx-ex32_1.htm (EX-32.1) — 10KB
• tcrx-ex32_2.htm (EX-32.2) — 11KB
• 0001193125-25-275933.txt ( ) — 7451KB
• tcrx-20250930.xsd (EX-101.SCH) — 1050KB
• tcrx-20250930_htm.xml (XML) — 909KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 6 Condensed Consolidated Balance Sheets 6 Condensed Consolidated Statements of Operations 7 Condensed Consolidated Statements of Stockholders' Equity 8 Condensed Consolidated Statements of Cash Flows 9 Notes to Unaudited Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 25 Item 4.

Controls and Procedures

Controls and Procedures 25 PART II. OTHER INFORMATION 26 Item 1.

Legal Proceedings

Legal Proceedings 26 Item 1A.

Risk Factors

Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 87 Item 3. Defaults Upon Senior Securities 87 Item 4. Mine Safety Disclosures 87 Item 5. Other Information 87 Item 6. Exhibits 87

Signatures

Signatures 89 5

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements. TScan Therapeutics, Inc. Condensed Consolidat ed Balance Sheets (in thousands, except share and per share data) (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 169,506 $ 178,689 Marketable securities 14,947 111,421 Prepaid expenses and other current assets 3,712 2,612 Total current assets 188,165 292,722 Property and equipment, net 9,303 7,242 Right-of-use assets 59,438 64,357 Restricted cash 5,031 5,031 Long-term deposit and other assets 288 1,766 Total assets $ 262,225 $ 371,118 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 6,353 $ 4,278 Accrued expenses and other current liabilities 10,765 15,410 Operating lease liability, current portion 6,904 4,570 Deferred revenue, current portion 5,186 11,698 Total current liabilities 29,208 35,956 Deferred revenue, net of current portion - 1,246 Operating lease liability, net of current portion 56,304 60,739 Long-term debt and accrued interest 32,414 32,072 Other long term liabilities 278 135 Total liabilities 118,204 130,148 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2025 and December 31, 2024 - - Voting common stock, $ 0.0001 par value; 300,000,000 shares authorized; 52,471,405 and 52,314,039 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 5 5 Non-voting common stock, $ 0.0001 par value; 10,000,000 shares authorized; 4,276,588 shares issued and outstanding at September 30, 2025 and December 31, 2024 1 1 Additional paid-in capital 625,898 616,009 Accumulated other comprehensive income 2 51 Accumulated deficit ( 481,885 ) ( 375,096 ) Total stockholders'